Clinical trials: Advanced Gastrointestinal Cancer
Rectal Cancer
Capecitabine in the Perioperative Treatment of Rectal Cancer
This study compares capecitabine with standard 5-FU in the perioperative treatment of locally advanced rectal cancer.
- Trial name
- Rektum-III (NCT01500993)
- Testing
- Capecitabine, 5-FU
- Where
- 14 sites in Germany
- Volunteers
- 401 people
- Sponsor
- Universitätsmedizin Mannheim
Adenocarcinoma of Rectum
Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients
Statins are widely used as lipid-lowering agents to lower cardiovascular risk with a favorable safety profile. In our recent in vitro study, the addition of simvastatin to chemoradiotherapy with 5-FU showed synergistic anticancer…
- Trial name
- NCT02161822
- Testing
- simvastatin
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Colorectal Cancer
A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer
To assess the safety and tolerability of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy
- Trial name
- NCT01801930
- Testing
- OCV-103 and OCV-104
- Where
- 3 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)
The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic hepatocellular carcinoma patients treated with NGR-hTNF as single agent.
- Trial name
- NCT00484211
- Testing
- NGR-hTNF
- Where
- 3 sites in Italy
- Volunteers
- 40 people
- Sponsor
- AGC Biologics S.p.A.
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Pancreatic Cancer, Gastric Cancer
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
This Phase 1 study will be a multicenter, single agent, dose escalation and dose expansion study conducted in patients with advanced late stage cancer (pancreatic or gastric including esophageal junction cancers) for which the…
- Trial name
- NCT05043987
- Testing
- CPO102
- Sponsor
- Conjupro Biotherapeutics, Inc.
Advanced Cancer, Breast Cancer
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
The Phase Ib and II cohorts will enroll patients with metistatic solid tumors. Phase II only will enroll the following patients: Patients with metastatic sarcoma to be enrolled in the following 4 arms: pembro plus gemcitabine…
- Conditions
- Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer
- Trial name
- NCT02331251
- Testing
- Pembrolizumab, Gemcitabine, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Western Regional Medical Center
Advanced Gastrointestinal Tumors
A Phase IIa Study Evaluating Injectable ALK-N001 in Patients With Advanced Gastrointestinal Tumors
This open-label, multicenter Phase IIa study is to evaluate the efficacy and safety of injectable ALK-N001 in patients with advanced gastrointestinal tumors, with the primary objective to assess its preliminary efficacy.
- Trial name
- NCT07826195
- Testing
- Injectable ALK-N001
- Volunteers
- 174 people
- Sponsor
- Zhejiang Anglikang Pharmaceutical Co., Ltd.
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Colorectal Cancer
Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC
The morbidity of colorectal cancer(CRC) is 10%～15% in China.mFolfox6 has become one of the standard regimes for metastatic colorectal cancer (mCRC).
- Trial name
- NCT02024412
- Testing
- monosialotetrahexosylganglioside Sodium
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
This is an open-label, single-center, single-arm, dose escalation and dose expansion Phase I/IIa study designed to determine the recommended Phase 2 dose (RP2D) and the safety and tolerability profile along with preliminary signs…
- Trial name
- NCT03707028
- Testing
- Rivoceranib, Paclitaxel
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Elevar Therapeutics
Solid Tumor, Colorectal Cancer
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in combination in participants with relapsed and/or…
- Conditions
- Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma
- Trial name
- NCT04553692
- Testing
- Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars)
- Where
- 58 sites in United States, Australia and 3 more
- Volunteers
- 272 people
- Sponsor
- IGM Biosciences, Inc.
Hepatocellular Carcinoma
HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
Hepatocellular carcinoma patients are mostly diagnosed at locally advanced stage. Nowadays, hepatic artery interventional therapy and/or systemic therapy are the main treatments options for these patients.
- Trial name
- HAICPD1-HCC (NCT03869034)
- Testing
- HAIC+PD1, HAIC
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Gastric Cancers
Correlation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer
1. Background Gastric cancer (GC) is a leading global cause of cancer-related mortality, with over 1 million new cases and 769,000 deaths in 2020.
- Trial name
- PDICI (NCT07003334)
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastric Cancer Metastatic to Liver
Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC
The overall incidence of liver metastases from gastric cancer is about 9.9%-18.7%. Gastric cancer has strong heterogeneity and rapid disease progression, and the prognosis of liver metastasis is poor.
- Trial name
- NCT05198856
- Testing
- Thalidomide Combined With Chemotherapy and Monotherapy
- Volunteers
- 106 people
- Sponsor
- Qilu Hospital of Shandong University
Metastatic Pancreatic Cancer, Pancreatic Cancer
Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
The primary objective of this study was to determine the progression free survival in patients with metastatic pancreatic cancer and in patients with locally advanced unresectable non-metastatic pancreatic cancer treated with a…
- Trial name
- FOLFIRINOX (NCT01523457)
- Testing
- Folfirinox
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Yale University
Carcinoma, Hepatocellular
A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma
Hepatocarcinoma (HCC) is the first cause of deaths due to cancer worldwide. More than one million two hundred thousand new patients are diagnosed each year.
- Trial name
- THBC002 (NCT00440934)
- Testing
- Amplitude-modulated electromagnetic fields
- Where
- Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pasche, Boris, M.D.
Hepatobiliary Cancer, Liver Cancer
Domvanalimab and Zimberelimab in Advanced Liver Cancers
The goal of this clinical trial is to learn about advanced liver and bile duct cancers. The main question it aims to answer is: If the combination of Domvanalimab and Zimberelimab are effective in treating advanced hepatobiliary…
- Conditions
- Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05724563
- Testing
- Zimberelimab, Domvanalimab
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Texas Southwestern Medical Center